<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Micronomicin (MCR) at a daily dose of 120 to 360 mg was administered to patients with severe <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> who had hematopoietic disorders as underlying diseases </plain></SENT>
<SENT sid="1" pm="."><plain>Efficacy and safety of the drug were evaluated </plain></SENT>
<SENT sid="2" pm="."><plain>The underlying diseases in the 56 patients included in the evaluation of efficacy were <z:hpo ids='HP_0004808'>acute myelocytic leukemia</z:hpo> (24 cases), <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (8), <z:hpo ids='HP_0004836'>acute promyelocytic leukemia</z:hpo> (6), <z:hpo ids='HP_0011009'>acute</z:hpo> monomyelocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (4), <z:hpo ids='HP_0004845'>acute monocytic leukemia</z:hpo> (1), <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">erythroleukemia</z:e> (1), <z:hpo ids='HP_0011010'>chronic</z:hpo> myelocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>-blastic crisis (4), malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (3), <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (2), and others (3) </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> were <z:mpath ids='MPATH_681'>septicemia</z:mpath> in 9 patients, suspected <z:mpath ids='MPATH_681'>septicemia</z:mpath> in 48, <z:hpo ids='HP_0011947'>respiratory tract infection</z:hpo> in 7, and <z:hpo ids='HP_0009789'>perianal abscess</z:hpo> in 2 </plain></SENT>
<SENT sid="4" pm="."><plain>The clinical efficacy of MCR was 'excellent' in 12 patients, 'good' in 17, 'fair' in 7, 'poor' in 30 for an efficacy rate of 43.9% </plain></SENT>
<SENT sid="5" pm="."><plain>The efficacy rate classified according to <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> was 22.2% in <z:mpath ids='MPATH_681'>septicemia</z:mpath>, 56.3% in suspected <z:mpath ids='MPATH_681'>septicemia</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain>The organisms isolated from the patients with <z:mpath ids='MPATH_681'>septicemia</z:mpath> were Escherichia coli in 2, Klebsiella pneumoniae in 2, Pseudomonas aeruginosa in 1, alpha-Streptococcus in 1, Serratia marcescens in 1, and Acinetobacter sp. in 1 </plain></SENT>
<SENT sid="7" pm="."><plain>The efficacy rate was 15.4% in the 13 patients whose causative organisms were identified </plain></SENT>
<SENT sid="8" pm="."><plain>The efficacy rate for patients who had failed to respond to prior antibiotic therapy was 43.9% </plain></SENT>
<SENT sid="9" pm="."><plain>The efficacy rate in patients (34 cases) with an initial neutrophil count less than 100/microliter was 44.1% </plain></SENT>
<SENT sid="10" pm="."><plain>Side effect which might have been caused by MCR was <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">skin eruption</z:e> in only one episode among 83 episodes those were evaluated for safety </plain></SENT>
</text></document>